文献速递临床试验与 GCP流行病学与生物统计新药、器械与细胞基因治疗研发

三联青蒿素联合疗法对比青蒿素联合疗法治疗无并发症恶性疟:多中心开放标签随机临床试验

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
PubMed 文献 · Lancet · 2020-03-11

这项多中心开放标签随机试验在8国18家医院招募1100例无并发症恶性疟患者,比较两种三联青蒿素联合疗法(TACT)与相应ACT的42天PCR校正疗效。双氢青蒿素-哌喹加甲氟喹疗效显著优于双氢青蒿素-哌喹(98% vs 48%),蒿甲醚-苯芴醇加阿莫地喹与蒿甲醚-苯芴醇相似(98% vs 97%)。两种TACT耐受性和安全性良好。

要点

  • 双氢青蒿素-哌喹加甲氟喹42天PCR校正疗效98%,显著优于双氢青蒿素-哌喹的48%。
  • 蒿甲醚-苯芴醇加阿莫地喹疗效98%,与蒿甲醚-苯芴醇97%相似。
  • 两种TACT耐受性良好,但双氢青蒿素-哌喹加甲氟喹早期呕吐更常见。

核心结论

  • 双氢青蒿素-哌喹加甲氟喹和蒿甲醚-苯芴醇加阿莫地喹两种TACT对无并发症恶性疟有效、耐受良好且安全,包括在青蒿素和ACT伙伴药物耐药地区。

研究设计与样本

  • 多中心、开放标签、随机临床试验,在8国18家医院和诊所招募1100例2-65岁无并发症恶性疟患者,按地点1:1随机分配至TACT或相应ACT,每周随访42天。

临床怎么用

  • 在青蒿素和ACT伙伴药物耐药地区,可考虑使用双氢青蒿素-哌喹加甲氟喹或蒿甲醚-苯芴醇加阿莫地喹TACT治疗无并发症恶性疟。
  • 使用含甲氟喹的TACT时需关注早期呕吐,含阿莫地喹的TACT需关注QT间期延长。

局限性

  • 开放标签设计可能影响不良事件报告。
  • 各治疗组样本量因地点和药物组合而异,部分比较的置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Artemisinin and partner-drug resistance in Plasmodium falciparum are major threats to malaria control and elimination. Triple artemisinin-based combination therapies (TACTs), which combine existing co-formulated ACTs with a second partner drug that is slowly eliminated, might provide effective treatment and delay emergence of antimalarial drug resistance. METHODS: In this multicentre, open-label, randomised trial, we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in eight countries. Eligible patients were aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum species, and a temperature of 37·5°C or higher, or a history of fever in the past 24 h. Patients were randomly assigned (1:1) to one of two treatments using block randomisation, depending on their location: in Thailand, Cambodia, Vietnam, and Myanmar patients were assigned to either dihydroartemisinin-piperaquine or dihydroartemisinin-piperaquine plus mefloquine; at three sites in Cambodia they were assigned to either artesunate-mefloquine or dihydroartemisinin-piperaquine plus mefloquine; and in Laos, Myanmar, Bangladesh, India, and the Democratic Republic of the Congo they were assigned to either artemether-lumefantrine or artemether-lumefantrine plus amodiaquine. All drugs were administered orally and doses varied by drug combination and site. Patients were followed-up weekly for 42 days. The primary endpoint was efficacy, defined by 42-day PCR-corrected adequate clinical and parasitological response. Primary analysis was by intention to treat. A detailed assessment of safety and tolerability of the study drugs was done in all patients randomly assigned to treatment. This study is registered at ClinicalTrials.gov, NCT02453308, and is complete. FINDINGS: Between Aug 7, 2015, and Feb 8, 2018, 1100 patients were given either dihydroartemisinin-piperaquine (183 [17%]), dihydroartemisinin-piperaquine plus mefloquine (269 [24%]), artesunate-mefloquine (73 [7%]), artemether-lumefantrine (289 [26%]), or artemether-lumefantrine plus amodiaquine (286 [26%]). The median age was 23 years (IQR 13 to 34) and 854 (78%) of 1100 patients were male. In Cambodia, Thailand, and Vietnam the 42-day PCR-corrected efficacy after dihydroartemisinin-piperaquine plus mefloquine was 98% (149 of 152; 95% CI 94 to 100) and after dihydroartemisinin-piperaquine was 48% (67 of 141; 95% CI 39 to 56; risk difference 51%, 95% CI 42 to 59; p<0·0001). Efficacy of dihydroartemisinin-piperaquine plus mefloquine in the three sites in Myanmar was 91% (42 of 46; 95% CI 79 to 98) versus 100% (42 of 42; 95% CI 92 to 100) after dihydroartemisinin-piperaquine (risk difference 9%, 95% CI 1 to 17; p=0·12). The 42-day PCR corrected efficacy of dihydroartemisinin-piperaquine plus mefloquine (96% [68 of 71; 95% CI 88 to 99]) was non-inferior to that of artesunate-mefloquine (95% [69 of 73; 95% CI 87 to 99]) in three sites in Cambodia (risk difference 1%; 95% CI -6 to 8; p=1·00). The overall 42-day PCR-corrected efficacy of artemether-lumefantrine plus amodiaquine (98% [281 of 286; 95% CI 97 to 99]) was similar to that of artemether-lumefantrine (97% [279 of 289; 95% CI 94 to 98]; risk difference 2%, 95% CI -1 to 4; p=0·30). Both TACTs were well tolerated, although early vomiting (within 1 h) was more frequent after dihydroartemisinin-piperaquine plus mefloquine (30 [3·8%] of 794) than after dihydroartemisinin-piperaquine (eight [1·5%] of 543; p=0·012). Vomiting after artemether-lumefantrine plus amodiaquine (22 [1·3%] of 1703) and artemether-lumefantrine (11 [0·6%] of 1721) was infrequent. Adding amodiaquine to artemether-lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared with baseline of 8·8 ms [SD 18·6] vs 0·9 ms [16·1]; p<0·01) but adding mefloquine to dihydroartemisinin-piperaquine did not (mean increase of 22·1 ms [SD 19·2] for dihydroartemisinin-piperaquine vs 20·8 ms [SD 17·8] for dihydroartemisinin-piperaquine plus mefloquine; p=0·50). INTERPRETATION: Dihydroartemisinin-piperaquine plus mefloquine and artemether-lumefantrine plus amodiaquine TACTs are efficacious, well tolerated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin and ACT partner-drug resistance. FUNDING: UK Department for International Development, Wellcome Trust, Bill & Melinda Gates Foundation, UK Medical Research Council, and US National Institutes of Health.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. van der Pluijm RW, Tripura R, Hoglund RM, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020. PMID: 32171078. doi:10.1016/S0140-6736(20)30552-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。